



Upconverting nanoparticle-containing erythrocyte-sized hemoglobin microgels that generate heat, oxygen and reactive oxygen species for suppressing hypoxic tumors

Hanju Kim^a, Johyun Yoon^a, Hwang Kyung Kim^a, Woo Tak Lee^a, Nguyen Thi Nguyen^a, Xuan Thien Le^a, Eun-Hee Lee^b, Eun Seong Lee^c, Kyung Taek Oh^d, Han-Gon Choi^e, Yu Seok Youn^{a,*}

^a School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do, 16419, Republic of Korea

^b College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong, 30019, Republic of Korea

^c Department of Biotechnology and Department of Biomedical-Chemical Engineering, the Catholic University of Korea, 43 Jibong-ro, Bucheon-si, Gyeonggi-do, 14662, Republic of Korea

^d College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul, 06974, Republic of Korea

^e College of Pharmacy, Hanyang University, 55, Hanyangdaehak-ro, Sangnok-gu, Ansan, 15588, Republic of Korea

ARTICLE INFO

Keywords:

Hemoglobin microgel
Upconversion
Photothermal therapy
Photodynamic therapy
Hypoxic tumors
Oxygen-generation

ABSTRACT

Inspired by erythrocytes that contain oxygen-carrying hemoglobin (Hb) and that exhibit photo-driven activity, we introduce homogenous-sized erythrocyte-like Hb microgel (μ Gel) systems (5–6 μ m) that can (i) emit heat, (ii) supply oxygen, and (iii) generate reactive oxygen species (ROS; $^1\text{O}_2$) in response to near-infrared (NIR) laser irradiation. Hb μ Gels consist of Hb, bovine serum albumin (BSA), chlorin e6 (Ce6) and erbium@lutetium upconverting nanoparticles (UCNPs; \sim 35 nm) that effectively convert 808 nm NIR light to 660 nm visible light. These Hb μ Gels are capable of releasing oxygen to help generate sufficient reactive oxygen species ($^1\text{O}_2$) from UCNPs/Ce6 under severely hypoxic condition upon NIR stimulation for efficient photodynamic activity. Moreover, the Hb μ Gels emit heat and increase surface temperature due to NIR light absorption by heme (iron protoporphyrin IX) and display photothermal activity. By changing the Hb/UCNP/Ce6 ratio and controlling the amount of NIR laser irradiation, it is possible to formulate bespoke Hb μ Gels with either photothermal or photodynamic activity or both in the context of combined therapeutic effect. These Hb μ Gels effectively suppress highly hypoxic 4T1 cell spheroid growth and xenograft mice tumors *in vivo*.

1. Introduction

Hemoglobin (Hb) is a natural tetrameric protein present in erythrocytes and comprising two α and two β polypeptide subunits that binds to oxygen [1]. The high oxygen-binding capacity of Hb has resulted in the development of many nano- or micro-scale Hb-based oxygen carriers (HBOCs) to supply oxygen as a blood substitute and mimic erythrocyte function [2]. Chemically-modified Hb conjugates (cross-linked, PEGylated, polymerized Hb, etc.) [3–6] and Hb-encapsulating particles (Hb-coated/containing liposomes/nanogels, microspheres, etc.) have shown high oxygen-supply potential. OxyglobinTM (Biopure, Inc., USA), a glutaraldehyde-crosslinked bovine Hb, was approved in Europe and

USA for veterinary use [5]. Moreover, Hb has much higher O₂-binding affinity than fluorocarbon-based oxygen carriers (FBOCs) like Fluosol-DATM, a 20% PFC formula [7], and is also known to generate hydroxy radicals ($\bullet\text{OH}$) via the Fenton reaction during autoxidation [8,9]. In addition, attempts have been made to mimic the shape, structure, and functions of Hb-containing erythrocytes to develop new biological templates [10–12]. Likewise, Hb is viewed as one of the most versatile materials for oxygen therapeutics.

Tumor hypoxia, which results from structural abnormalities of the tumor vasculature, is considered a critical hurdle in cancer therapy. Solid tumors contain numerous hypoxic regions because their vasculature is unable to supply sufficient oxygen to each cell [13,14]. The

Peer review under responsibility of KeAi Communications Co., Ltd.

* Corresponding author.

E-mail address: ysyoun@skku.edu (Y.S. Youn).

<https://doi.org/10.1016/j.bioactmat.2022.09.020>

Received 21 June 2022; Received in revised form 16 September 2022; Accepted 19 September 2022

Available online 28 September 2022

2452-199X/© 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

reduced oxygen level in hypoxic tumors impairs the therapeutic efficiency of chemotherapeutics, radioactive medicines, and photosensitizing agents that require oxygen for activity. Oxygen level of severe hypoxic tumors has been measured as less than 5 mmHg (<0.7%) compared to the 30–52 mmHg (3.9–6.8%) oxygen level of normal tissues [15]. Hence, sufficient oxygenation is essential for treating hypoxic tumors, and many strategies to elevate oxygen level have been investigated to overcome hypoxia-induced resistance to cancer treatment [16–23].

Photodynamic therapy (PDT) is a highly effective tumor treatment. Photosensitizing agents (PS) are able to generate reactive oxygen species (ROS) such as hydroxy radicals and singlet oxygen ($^1\text{O}_2$) from oxygen molecules in response to near-infrared (NIR) irradiation; these ROS then critically damage tumor cells [24,25]. However, the therapeutic performance of PDT is inhibited in hypoxic tumor regions because of the dependence of this method on tissue oxygen level and light intensity. Moreover, most PS agents have a maximum absorption of ~ 660 nm, and light of this wavelength cannot fully penetrate deep tissues compared to NIR light (700–980 nm) [26–28]. Upconverting nanoparticles (UCNPs) capable of emitting shorter wavelength light from longer excitation light based on the anti-Stokes phenomenon have been utilized to increase penetration depth and illumination efficiency. In particular, UCNPs that absorb light at wavelengths of 700–980 nm and emit light of ~ 660 nm can trigger PS in the body. Lanthanide element-doped core@shell

UCNPs consisting of a sensitizer and an activator have been widely used to maximize upconversion activity [29–32].

Hyperthermia is another antitumor therapy. Severe hyperthermia ($>48^\circ\text{C}$ for 10 min) is known to induce rapid apoptosis and irreversible death of tumor cells [33]. By contrast, mild hyperthermia of $39\text{--}42^\circ\text{C}$ enhances the delivery of antitumor therapeutics to the tumor due to increased blood flow and improved vascular permeability of either the drug or nanoparticles due to enlargement of the pores of tumor blood vessels [34–36]. Also, mild hyperthermia helps increase oxygen levels (e.g., partial oxygen pressure (pO_2) and oxy-hemoglobin (HbO_2)) in solid tumors, potentiating the antitumor efficacy of chemotherapeutics [37,38]. Consequently, using hyperthermia in conjunction with primary antitumor modalities can enhance the effectiveness of antitumor therapy. Many conventional photothermal agents, such as indocyanine green, IR780, and gold nanorods, can be used to control the surface temperature in response to NIR laser irradiation depending upon laser intensity, irradiation time, and the concentration of photothermal agents among other factors [39–42].

Herein, we introduce *in situ* injectable versatile erythrocyte-sized microgel platforms ($5\text{--}6\ \mu\text{m}$) with controlled photothermal and photodynamic activity that generate heat, O_2 , and ROS in response to NIR light. Microgels (Hb μGel) comprised (i) hemoglobin to supply oxygen and emit heat in response to 808 nm laser irradiation, (ii) albumin to stabilize the μGel system, and (iii) UCNPs to emit ~ 660 nm light in




Fig. 1. Schematic illustration showing heat, oxygen, and reactive oxygen species-generating erythrocyte-sized hemoglobin microgels (A) and the use of these microgels for photothermal and photodynamic therapy in hypoxic tumors (B).

response to deep-penetrating 808 nm laser illumination to activate a photosensitizing agent (Ce6) and produce singlet oxygen (1O_2). We hypothesized that these Hb μ Gels would be able to elevate the O_2 level in hypoxic tumors and potentiate the cytotoxic effect of photodynamic therapy in conjunction with UCNPs. In addition, we posit that heat emission from Hb in response to NIR laser irradiation (808 nm) would help expand the tumor vasculature due to locally elevated temperature (41–42 °C) or could ablate malignant tumors due to severe hyperthermia (>48 °C). Our UCNP/Ce6-loaded Hb μ Gels are versatile photothermal and photodynamic injectable agents that can overcome the obstacles associated with treatment of hypoxic tumors (Fig. 1).

2. Results and discussion

2.1. Fabrication and characterization of UCNPs

First, we fabricated UCNPs capable of activating a photosensitizer (Ce6) and incorporating into the Hb microgel structure. Our goal was to fabricate UCNPs that efficiently emit 660 nm light upon 808 nm excitation for Ce6 activation. We sought to prepare simple UCNPs consisting of only two components, an erbium (Er) core and a lutetium (Lu) shell, that predominantly emitted red fluorescence emission (~660 nm) in response to 808 nm NIR light. The optimized 660 nm emission of UCNPs is inevitable because the quantum efficiency of regular UCNPs is usually very low (<1%) [43,44]. The highest NIR-to-visible efficiency for UCNPs is 5% even when using deeply penetrating long wavelength light (800–1200 nm) and high irradiation (~ 100 W/cm²) [45]. Furthermore, UCNPs should be able to disperse well in water to prevent rapid sedimentation or aggregation in response to a high metal density during the emulsification step.

As shown in Fig. 2A, core-only (Er) and core@shell (Er/Lu) UCNPs typically had sharpened edges and were hexagonal in shape. The size of

Er core nanoparticles was optimized by varying the Er/F ratio and NH_4F amount (Fig. S1). The final particle sizes of core-only (Er) and core@shell (Er/Lu) UCNPs were ~ 25 and ~ 35 nm, respectively (Figs. 2B and S1), indicating that these particles were small enough for colloidal dispersion without critical sedimentation (Fig. 2C). Unlike other conventional lanthanide-based UCNPs (herein, $NaYF_4: Yb, Nd, Er@NaLuF_4$ UCNPs), the prepared Er@Lu ($NaErF_4@NaLuF_4$) UCNPs presented predominant red emission (>96.7%) around 660 nm but negligible green emission (<3.3%) around ~ 540 nm, which effectively activated Ce6. Also, our $NaErF_4@NaLuF_4$ UCNPs were found to have significantly higher emission intensity (>2.7 fold) around 660 nm, when compared with conventional formula for $NaYF_4: Yb, Nd, Er@NaLuF_4$ UCNPs (Fig. S2) in response to 808 nm laser irradiation [29,30].

In our Er@Lu UCNPs ($NaErF_4@NaLuF_4$ NPs), Er^{3+} played both roles as sensitizer and activator, absorbing photons and donating the photons to Er^{3+} itself and thereby undergoing multi-step excitation owing to energy transfer [46,47]. This process generates upconverting luminescence. Moreover, the Lu^{3+} -shell plays a role in confining the excited energy within core lattices and strengthening the upconversion emission by preventing surface quenching [29,30,48]. TEM images, element mapping, and EDS spectra for Er@Lu UCNPs shown in Fig. 2D, E and F, respectively, revealed the distribution of Er and Lu in the core and shell of UCNPs. X-ray diffraction (XRD) spectral patterns of the prepared Er@Lu UCNPs ($NaErF_4@NaLuF_4$ Core@Shell NPs) were consistent with the representative peaks of previously reported UCNPs [30,49]: all peaks corresponded to (100) (110) (101) (200) (111) (201) (210) (211) (112) (220) and (311) lattice planes of pure hexagonal phase of $NaErF_4$ standard pattern (JCPDS #27–0689). The overall result indicated that our Er@Lu UCNPs were successfully synthesized with the hexagonal phase crystals (Fig. 2G) and strong performance for photodynamic activity [50,51].




Fig. 2. (A) TEM images of (a) core only and (b) core@shell UCNPs. (B) Histograms of particle sizes of (a) core only and (b) core@shell UCNPs. (C) Photographs of dispersed solutions of Er or Er@Lu UCNPs emitting red fluorescence when irradiated with 808 nm laser. (D) (a) TEM image of Er@Lu UCNPs, (b) and (c) element mapping of core and shell, respectively, (d) electron mapping, (e) merged image. (E) Er and Lu distribution profiles of UCNPs. (F) EDS (electron dispersive spectroscopy) spectrum of Er@Lu UCNPs. (G) XRD spectra of (a) core UCNPs, (b) core@shell UCNPs, (c) JCPDS: 27–0689 ($NaErF_4$).

2.2. Preparation and characterization of hemoglobin microgels

Erythrocytes are the most abundant cells in blood and have multiple biological functions including oxygen delivery [12]. Erythrocytes are viewed as natural transport agents for drug delivery because there is abundant intracellular space for drug loading and their physical structure and size can aid in immune cell evasion [11]. Drug-encapsulated or surface-modified erythrocytes can function as circulating depot systems by protecting the drugs from phagocytosis, resulting in gradual release of drugs into the blood and attenuation of drug-related toxicity [52]. There have been several successful attempts to mimic the biological functions and physical shape/structure of erythrocytes for drug delivery [3,10,11]. Precise micro-size control of oxygen carriers similar to erythrocytes is important because the size of oxygen carriers affects

physical contact with relevant cells and cellular uptake by adjoining cells as well as phagocytic cells [53].

We prepared hemoglobin microgels (Hb μ Gels) similar in size to natural erythrocytes and with a roughly similar shape though without the concave depression characteristic of natural erythrocytes. Hb μ Gels were facilely prepared using a well-established membrane emulsification method involving the use of Shirasu porous glass (SPG) membranes (Fig. S3). In agreement with the significant accomplishments by Ito et al. [53–55], the size of our Hb μ Gels could be controlled by adjusting the pore size of the SPG membranes; in particular, extrusion emulsification (w/o) using a hydrophobic SPG membrane with 3- μ m pores resulted in the best size matches of our Hb μ Gels (5–6 μ m) with that of erythrocytes (5–7 μ m) (Fig. S4). As shown in Fig. 3A, our Hb μ Gels prepared using different amounts of hemoglobin and albumin (fluorescein-labelled)




Fig. 3. (A) CLSM images of microgels of Hb and BSA using various weight-based feed ratios (Hb:BSA) of (i) 0:16, (ii) 6:10, and (iii) 10:6 (Hb and BSA-FITC fluorescence measured using Ex/Em wavelengths of 549/628 nm and 495/519 nm, respectively). (B) SEM (left), fluorescence microscopy (right top), and CLSM (right bottom) images of Hb₆ μ Gels. (C) Focused ion beam (FIB)-based SEM images of Er@Lu UCNP-loaded Hb₆ μ Gel. (D) FIB-TEM images of Er@Lu UCNP-loaded Hb₆ μ Gel. (E) FIB-SEM images of Er@Lu UCNP-loaded Hb₆ μ Gels prepared using different UCNP amounts (a: 120 mg, b: 60 mg, c: 30 mg, d: 0 mg). (F) Photographs of (a) dry powder and (b) dispersed solutions of Hb₀ μ Gel, Hb₆ μ Gel and Hb₁₀ μ Gel. (G) CLSM images of Hb₆ microgels with Er@Lu UCNPs and Ce6.

were visualized by confocal laser scanning microscopy (CLSM). Red or green fluorescence indicated the presence of Hb and BSA, respectively. A greater Hb feed amount led to greater red fluorescence intensity, indicating higher incorporation of Hb into the respective Hb μ Gels. Hb₆ μ Gels were homogeneously spherical and highly uniform in size (~6 μ m) (Fig. 3B). Our next important goal was to incorporate large quantities of Er@Lu UCNP into the Hb μ Gel during membrane emulsification and gelation. Er and Lu are very heavy (density: 9.2 and 9.7 $\text{g}\cdot\text{cm}^{-3}$, respectively), and the surfaces of oleate-capped Er@Lu UCNP are hydrophobic and minimally water-dispersible. Sedimentation and aggregation of Er@Lu UCNP should be prevented by substitution with the hydrophilic polyacrylic acid (PAA) [56]. The resulting PAA-coated Er@Lu UCNP were well dispersed in water and phosphate buffer over 12 h without significant precipitation or particle agglomeration, when compared with oleate (OA)-coated Er@Lu UCNP. This enhanced dispersibility probably ensured their stable incorporation into the water phase during membrane emulsification (<60 min) (Fig. S5), showing the relatively high encapsulation efficiency of >63%.

Incorporation of UCNP into Hb μ Gels was identified by focused ion beam (FIB)-scanning electron microscopy (SEM) and transmission electron microscopy (TEM); the water phase-dispersed UCNP were stably embedded throughout the internal network structure of Hb μ Gels based on cross-sectional surface analysis (Fig. 3C), and the presence of incorporated UCNP was also confirmed using TEM (Fig. 3D). As shown in Fig. 3E, the amount of incorporated UCNP was proportional to the respective feed amount (0–120 mg). As-prepared Er@Lu UCNP-loaded Hb μ Gels prepared at different feed amount ratios of Hb and BSA (0:16, 6:10, and 10:6) had distinctive powder colors and were well dispersed in solution as fine micro-suspensions without aggregation (Fig. 3F). The photosensitizer Ce6 was directly incorporated into the Hb₆ μ Gels (+UCNP) at the final step for photodynamic activity, and the Ce6-containing Hb₆ μ Gels were visualized using CLSM at wavelengths appropriate for Hb and Ce6, respectively (Fig. 3G). In general, surface Ce6-conjugated UCNP (i.e., UCNP@SiO₂) have been utilized in intravenous route for photodynamic therapy in terms of high energy transfer. However, a direct loading method for Ce6 was considered more efficient for local delivery because additional Ce6 conjugation step onto UCNP was associated with practical inefficiency at our microgel system, such as, restricted conjugation yield and reduced dispersability of UCNP owing to low Ce6 solubility.

2.3. Photothermal activity of Hb μ Gels

We next examined the pharmaceutical performance of the various Hb μ Gels including Er@Lu UCNP/Ce6-loaded Hb μ Gels in terms of the generation of heat, oxygen and singlet oxygen (ROS). First, the photothermal ability of Hb μ Gels was evaluated. As with porphyrins with pyrrole rings and unsaturated linkers, heme (iron protoporphyrin IX), a major component of Hb, efficiently absorbs visible bandwidth light much more than other blood components [57]. In particular, heme derivatives coordinated with metal ions effectively absorb light and have strong photothermal as well as photodynamic effects [57,58]. For example, porphyrin nanovesicles were shown to display strong hyperthermia comparable to that of gold nanorods in response to 673 nm laser irradiation [58]. Previously, we reported concentration-dependent hyperthermal activity in *in situ* PEGylated hemoglobin hydrogels; these hydrogels had surface temperatures of ~70 °C at 100 mg/ml feed concentration under 808 nm irradiation [59]. This was due to considerable absorption of NIR red light (700–900 nm) by hemoglobin. Similar to our previous findings [59], the Hb μ Gels showed hyperthermal activity under 808 nm laser irradiation that was comparable to that of naïve Hb (Fig. S6).

As shown in Figs. 4A, B and S7, Hb₁₀ or Hb₆ μ Gels (30 mg/mL) had surface temperatures up to ~58 and 46 °C, respectively, after 15 min under 808 nm-laser irradiation (1.5 W/cm²), whereas Hb₀ μ Gels (BSA μ Gel without any Hb) emitted little heat under the same conditions. The

photothermal activity of Hb μ Gels according to Hb feed amount was also visualized by photothermal camera (Fig. 4C). Hb μ Gels showed photothermal activity only when irradiated with 808 nm laser light. Local hyperthermia around 41–42 °C could be precisely tuned by controlling irradiation time and intensity (Fig. 4D). Mild hyperthermia (42–48 °C) of mice tumors was achieved using Hb μ Gels (Hb:BSA = 10:6 or 6:10) and 808 nm laser irradiation, whereas the surface temperature of mice tumors treated with PBS or Hb₀ μ Gel did not increase appreciably (Figs. 4E, F and S8).

2.4. Oxygen-carrying and photodynamic activity of Hb μ Gels

Circular dichroism spectra of Hb μ Gels showed little similarity with those of its major component materials (Hb and BSA) in the wavelength range of 190–260 nm. Wavelengths of each Hb μ Gel formula (Hb:BSA = 10:6, 6:10 or 0:16, respectively) appeared to be around 228–234 nm, whereas Hb and BSA had 222 or 210 nm troughs because of the large size of Hb μ Gels (>5 μ m) (Fig. 5A). The major hemoglobin form used in this study was acellular methemoglobin (Fe³⁺), which has a low oxygen-binding/carrying affinity [5]. Therefore, met-Hb should be reduced to ferrous Hb (Fe²⁺), which is more likely to bind to oxygen as an oxyhemoglobin; ascorbic acid can then be used to reduce met-Hb to ferrous Hb for further facile conversion to (de)oxy-Hb.

Representative UV-VIS spectra peaks for met-Hb and oxy-Hb were observed at ~406 and ~412 nm, respectively [60,61]. Similarly, our Hb₆ μ Gel and ascorbic acid-reduced Hb₆ μ Gel (presumably oxygenated Hb μ Gel) had UV-VIS spectral peaks at ~408 and ~413 nm, respectively (Fig. 5B). However, our Hb₆ μ Gel did not display two distinct peaks at ~540 and ~575 nm, which are representative of oxy-Hb (data not shown). The colors of both Hb and Hb₆ μ Gel solutions became browner upon addition of ascorbic acid (final concentration of 6 mM) (Fig. 5C). As shown in Fig. 5D, the nitrogen-purged hypoxic Hb₆ μ Gel sample contained very little oxygen, whereas oxygenated Hb₆ μ Gel showed immediate increase in the O₂ concentration in a hypoxic solution. Furthermore, oxygenated Hb₆ μ Gel with ascorbic acid (6 mM) increased the O₂ concentration significantly (vs. Hb₆ μ Gel without ascorbic acid), and this O₂ concentration was maintained for 20 min. The increase of O₂ concentration by Hb₆ μ Gel (+ ascorbic acid & oxygen) was higher than that of Hb₀ μ Gel (+ PFC & oxygen). However, Hb₀ μ Gel (+ PFC & oxygen), which included a PFC-loaded BSA nanoemulsion (PFC/BSA-NE; Fig. S9), exhibited a second episode of oxygen release when treated with ultrasound for 5 min. These results indicated that oxygenated Hb₆ μ Gels (if additionally formulated with PFC/BSA-NE) can deliver a prolonged oxygenation effect under hypoxic conditions. Finally, the singlet oxygen (¹O₂)-generating ability of each Hb μ Gel was evaluated under normoxic, hypoxic, or oxygenated conditions.

As mentioned above, ¹O₂-generation efficiency is critically determined by oxygen level, from which singlet oxygen are generated. Thus, photodynamic antitumor therapy using photosensitizers is not effective in severely hypoxic cancers. Nitrogen-purged hypoxic UCNP/Ce6-loaded Hb₆ μ Gel samples generated no significant ¹O₂, whereas oxygenated UCNP/Ce6-loaded Hb₆ μ Gels induced ¹O₂ production even under hypoxic conditions. Importantly, UCNP/Ce6-loaded Hb₆ μ Gels (+ ascorbic acid & oxygen) resulted in gradual generation of ¹O₂ over 60 min, and the ¹O₂-generating ability of these gels was higher than that of UCNP/Ce6-loaded Hb₀ μ Gels (+ PFC & oxygen) (Fig. 5E). Singlet oxygen sensor green (SOSG) oxidized by singlet oxygen (¹O₂) forms SOSG endoperoxide (SOSG-EP), providing strong fluorescence signals. The SOSG signal intensity from microplate wells for corresponding samples were visualized at predetermined times using a fluorescence imaging system (NeoScience, Suwon, Korea). As shown in Fig. 5F, the SOSG signal intensity of the groups with supplied oxygen gradually increased with the color change from green to red. Especially, UCNP/Ce6-loaded Hb₆ μ Gels (+ ascorbic acid & O₂) displayed the strongest red fluorescence signal at 60 min, when compared with other groups.




Fig. 4. (A) Kinetic changes in surface temperatures of Hb μ Gels (20 or 30 mg/ml each) under NIR laser irradiation (808 nm, 1.5 W/cm²). ⁺P and ^{*}P < 0.006 over Hb₁₀ μ Gel (20) and Hb₆ μ Gel (20), respectively. (B) Thermographic images of PBS and Hb μ Gels under NIR laser irradiation (808 nm, 1.5 W/cm²). (C) Fluorescence and thermographic images of Hb₀, Hb₆, and Hb₁₀ μ Gels irradiated by laser (808 nm, 1.5 W/cm²). (D) Mild hyperthermia (41–42 °C) induced by Hb₀, Hb₆ and Hb₁₀ μ Gels with alternation of on/off 808 nm light irradiation. ⁺P and ^{*}P < 0.005 over Hb₀ μ Gel +808 nm and Hb₆ μ Gel +808 nm, respectively. (E) Tumor temperature change profiles of Hb μ Gel groups with or without 808 nm laser irradiation (0.3–0.5 W/cm²) in a mild hyperthermia setting (41–42 °C). (F) *In vivo* whole-body thermal images of 4 T1 tumor-bearing mice treated with PBS, Hb₀, Hb₆ or Hb₁₀ μ Gels.




Fig. 5. (A) Circular dichroism spectra of PBS, naive Hb, BSA or Hb₀, Hb₆, and Hb₁₀ μ Gels. (B) UV-VIS spectra of naive or ascorbic acid-treated Hb₆ μ Gels. (C) Singlet oxygen generation profiles of PBS and the various Hb μ Gel groups under different conditions. (D) Photographs of naive Hb (a) and Hb₆ μ Gel (c) or ascorbic acid-treated-Hb (b) and ascorbic acid-treated-Hb₆ μ Gel (d), and ascorbic acid-treated/oxygenated-Hb₆ μ Gel (e). (E) Oxygen generation profiles of the various Hb₆ μ Gel groups under different conditions. (F) SOSG fluorescence profiles showing the amount of singlet oxygen produced at each time point (Ex/Em = 485/538 nm). ^{*}P < 0.01 over Hb₀ μ Gel + PFC + O₂ + US(+). (F) Fluorescence images of each microplate well showing the production level of singlet oxygen at various time points: (a) PBS; (b) Hb₆ μ Gel + ascorbic acid (6 mM) + O₂; (c) Hb₆ μ Gel + O₂; (d) Hb₆ μ Gel + PFC + O₂ + US(-); (e) Hb₆ μ Gel + PFC + O₂ + US(+); (f) Hb₆ μ Gel + N₂.

2.5. *In vitro* cytotoxic evaluation of Hb μ Gels in hypoxic cell spheroids

We next evaluated the cytotoxicity of our UCNP/Ce6-loaded Hb μ Gels (Hb₁₀ or Hb₆ μ Gel) to hypoxic 4T1 cell spheroids. Given the relatively large size (~6 μ m) of our Hb μ Gels compared to 4T1 cells, we

did not use 2D cell beds for cytotoxicity evaluation because these cell beds became tightly attached and covered with a large quantity of Hb μ Gel even at a relatively low concentration (0.5–2.0 mg/ml) vs. the concentration used in the spheroid system (>20 mg/ml), which presumably resulted in temporary unwanted hypoxia, abnormal physiology

and eventually cell death (Fig. S10). Hence, three dimensional 4T1 spheroids (~500 μm) were chosen for the staining-based *in vitro* cytotoxicity evaluations, such as, Live/Dead™, ROS production and HIF-1α assay. As shown in Fig. 6A, UCNP/Ce6-loaded Hb μGels were well dispersed in media and contacted the outer layer of 4T1 spheroids. Hb μGels are unlikely to penetrate cells or the deep inner space of spheroids given their large size (5–6 μm vs. each cell 30–40 μm) (Fig. S11). Hypoxia was achieved in a hypoxic chamber using a hypoxic gas stream (5% CO₂/95% N₂) and confirmed by visualizing hypoxia-inducible factor (HIF)-1α expression.

As shown in Fig. 6B, spheroids subjected to hypoxic conditions stained strongly with anti-HIF-1α antibody (emitted bright green fluorescence). By contrast, normoxic spheroids did not stain with anti-HIF-1α antibody [23]. Significantly, 4T1 spheroids treated with either UCNP/Ce6-loaded Hb₆ μGels (+ ascorbic acid & oxygen) or UCNP/Ce6-loaded Hb₀ μGels (+ PFC & oxygen + US scan) did not produce a hypoxic fluorescence signal. Intracellular ¹O₂ generation in 4T1 cell spheroids was visualized by CLSM. Under hypoxic conditions, all 4T1 cell spheroids incubated with UCNP/Ce6-loaded Hb μGels displayed negligible fluorescence signals, indicating the absence of intracellular ¹O₂ based on CellROX® Deep Red dye detection regardless of 808-nm laser irradiation (Fig. S12). By contrast, when irradiated with 808 nm laser light, all 4T1 cell spheroids incubated under normoxic or oxygenated conditions with UCNP/Ce6-loaded Hb₆ μGel (+ ascorbic

acid & oxygen) or UCNP/Ce6-loaded Hb₀ μGel (+ PFC & oxygen + US scan) emitted strong fluorescence signals. This indicated that our UCNP/Ce6-loaded Hb₆ μGels were able to release or generate both O₂ and ¹O₂ under hypoxic conditions and thereby kill spheroids (Fig. 6C). The UCNP/Ce6-loaded Hb₆ μGels (+ ascorbic acid & oxygen + 808 nm laser) effectively killed spheroids, whereas naïve UCNP/Ce6-loaded Hb₆ μGels were unable to kill spheroids under hypoxic conditions despite 808 nm laser irradiation. The cytotoxicity of UCNP/Ce6-loaded Hb₆ μGels (+ ascorbic acid & oxygen + 808 nm laser) was comparable to that of UCNP/Ce6-loaded Hb₀ μGels (+ PFC & oxygen + US scan + 808 nm laser) (Fig. 6D).

As shown in Fig. 6E, UCNP/Ce6-loaded Hb₀ μGels displayed a significant photodynamic activity-based cytotoxic effect at a low concentration (20 mg/mL; 808 nm laser 30 min) and under normoxic conditions, while Hb₆ μGels (30 mg/mL without Ce6/UCNPs) showed notable photothermal activity-based cytotoxicity in response to 808 nm laser irradiation (1.5 W/cm²) for 30 min. As shown in Fig. 6F, UCNP/Ce6-loaded Hb₆ μGels had significant cytotoxic activity with mild hyperthermia (41–42 °C) in conjunction with photodynamic activity under normoxia, whereas Hb₆ μGels were unable to kill 4T1 spheroids despite mild hyperthermia. The strong photothermal activity induced by 808 nm laser irradiation (1.5 W/cm² for 30 min) of Hb₆ μGels (~40 mg/mL) effectively killed spheroids, as indicated by the absence of green fluorescence. Additionally, the 808 nm laser irradiation (1.5 W/cm² for 60




Fig. 6. (A) CLSM images of a 4T1 cell spheroid with dispersed Hb₆ μGel. (B) CLSM images of HIF-1α staining in 4T1 cell spheroids treated with PBS or various Hb μGels under normoxic, oxygenated or hypoxic conditions. (C) CLSM images of intracellular ROS production in 4T1 cell spheroids treated with Hb μGels (+UCNPs/Ce6) with or without 808 nm laser irradiation under normoxic or hypoxic conditions. (D) CLSM images of live/dead 4T1 cell spheroids incubated with Hb μGels (+UCNPs/Ce6) with or without 808 nm laser irradiation under hypoxic or oxygenated conditions. (E) CLSM images of live/dead 4T1 cell spheroids incubated with PBS, Hb₆ μGel (+UCNPs/Ce6) or Hb₁₀ μGel with or without 808 nm laser irradiation under normoxic conditions. (F) CLSM images of live/dead 4T1 cell spheroids incubated with PBS or Hb₆ μGel (+UCNPs/Ce6) with or without 808 nm laser irradiation specifically adjusted to induce mild (41–42 °C) or high (>48 °C) surface temperatures. Green and red represent live and dead cells, respectively.

min) alone hardly exhibited significant temperature increase and deleterious effect on the 4T1 spheroid viability (Figs. 6D, E and S12). Therefore, the overall cytotoxicity to 4T1 tumor cells was obviously due to the combined effects by photothermal and photodynamic activity aided by O₂ supply.

2.6. *In vivo* imaging and tumor oxygenation of Hb₆ μGels in hypoxic mice tumors

The presence of metal (Er/Lu) components was clearly detected in UCNP/Ce6-loaded Hb₆ μGels by computed tomography (CT). Especially, Lu shell-based UCNPs possess prominent spectral X-ray CT performance, which is considered even better than that of clinical used Iohexol® and provides improved diagnostic interpretation [62]. As shown in Fig. 7A, UCNP/Ce6-loaded Hb₆ μGels were detected at the injection site of mouse tumors up to 1 day after injection. However, a negligible quantity of UCNP/Ce6-loaded Hb₆ μGel was present at the tumor site on day 7. After intratumoral injection of UCNP/Ce6-loaded Hb₆ μGels (including Hb

and Cy5.5-BSA) in 4T1 tumor-bearing mice, Hb and Cy5.5 fluorescence were visualized. Considerable amounts of fluorescence from both Hb and Cy5.5 were present for up to 12 h, but the NIR-fluorescence signals decreased gradually and then faded at 168 h after intratumoral injection (Figs. 7B and S13). Accumulation of oxygen (as HbO₂) in the 4T1 tumors of mice was visualized by photoacoustic (PA) analyses with high resolution and deep imaging depth (Fig. 7C). Intratumoral injection of PBS and hypoxic Hb₆ μGel (purged with N₂) generated very little oxygen (20–30% over 60 min). However, intratumoral injection of Hb₆ μGel (+ ascorbic acid & oxygen) effectively elevated the tumor oxygen level (>60%) at 0–30 min, comparable to that achieved by Hb₀ μGel (+ PFC + US(+)) (>55–65% over 30 min) (Fig. 7D). These findings demonstrated that our Hb₆ μGel were able to supply oxygen to ameliorate hypoxia in solid tumors.




Fig. 7. (A) Computerized tomography (CT) images of 4T1 tumor-bearing mice intratumorally injected with UCNP-loaded Hb₆ μGels. (B) *In vivo* visualization of 4T1 tumor-bearing mouse after intratumoral injection of Hb₆ μGel based on Cy5.5 and Hb fluorescence at 630 and 730 nm, respectively. (C) Photoacoustic images showing 4T1 tumor oxygenation before and after intratumoral injection of PBS or various Hb₆ μGels (+ ascorbic acid or PFC) with or without ultrasound (US) treatment. (D) Oxygen level profile of 4T1 tumors before and after intratumoral injection of PBS or various Hb₆ μGels (+ ascorbic acid or PFC) under different conditions. ⁺*P* < 0.003, ^{*}*P* < 0.001 and ^{*}*P* < 0.05 over the group of Hb₀ μGel + PFC + O₂ + US(-). (E) Brief schedule for *in vivo* antitumor efficacy experiment using a 4T1 xenograft mice model.

2.7. In vivo antitumor efficacy of intratumor-injected Hb μ Gels in hypoxic mice tumors

Our final aim was to evaluate the antitumor effect of UCNP/Ce6-loaded Hb μ Gels in a hypoxic 4T1 tumor-bearing mouse model (Fig. 7E). Mice having tumors of 120–150 mm³ were randomly divided into seven groups (G1–G7). Hb μ Gel samples for each group were designated to reveal the differences in antitumor efficacy in terms of hemoglobin content, photodynamic activity, oxygen supplying effect

and hyperthermal degree (NIR laser irradiation time etc.). The detailed sample descriptions were presented in Fig. S14. The NIR irradiations for the mild and strong temperature setting and ultrasound scan were performed for 20, 30 and 60 min, respectively. Tumor volumes were measured for 20 days after treatment (Fig. 8A and B). Tumor volumes on day 20 for groups G1 - G7 were 1089.9 \pm 79.2, 986.7 \pm 22.8, 916.5 \pm 104.7, 893.1 \pm 22.7, 484.7 \pm 23.8, 106.8 \pm 83.5, and 49.8 \pm 37.2 mm³, respectively. Compared with G5 mice, there was less opportunity for release and supply of oxygen (from PFC) in mice in G6 due to the




Fig. 8. (A) Profile of tumor volumes of 4T1 tumor-bearing mice treated with G1 - PBS (non-treated); G2 - Hb₆ μ Gel + 808 nm (+) under a mild temperature (41–42 °C) setting; G3 - Hb₆ μ Gel (+UCNPs/Ce6) previously treated with nitrogen to maintain a hypoxic state + 808 nm (+) (1.5 W/cm² for 20 min); G4 - Hb₆ μ Gel (+UCNPs/Ce6) + ascorbic acid + O₂ + 808 nm (-); G5 - Hb₆ microgel (+UCNPs/Ce6) + PFC + O₂ + 808 nm (+) + US(+) (60 min); G6 - Hb₁₀ μ Gel (+UCNPs) + 808 nm (+) (1.5 W/cm² for 30 min) under strong hyperthermia (>48 °C) and G7 - Hb₆ μ Gel (+UCNPs/Ce6) + ascorbic acid + O₂ + 808 nm (+) under a mild temperature (41–42 °C) setting. **P* < 0.003, **P* < 0.001 over G5 and ***P* < 0.01 over G4. (B) Individual tumor volume profiles of each mouse group (G1–G7). (C) Photographs of tumors excised from each treatment group. (D) Representative photographs of 4T1-tumor-bearing mice at the indicated days after treatment. (E) Weight of mice over time. (F) Microscopic photographs showing H&E and TUNEL staining of tumor slices from mice in each treatment group. (G) Immunofluorescence imaging of tumor slices from mice treated with each sample. Cell nuclei, blood vessels, and hypoxic regions were stained with DAPI (blue), anti-CD31 antibody (red), and antipimonidazole (green), respectively.

absence of ultrasound treatment. Tumors in G6 or G7 groups were the most noticeably suppressed after treatment with UCNP/Ce6-loaded Hb μ Gels designed to achieve strong hyperthermia (>48 °C) or photodynamic performance under a mild temperature (41–42 °C) in addition to increasing oxygen levels (Figs. 8C, D and S15). Despite only single treatment during entire *in vivo* experiment, tumors in G6 or G7 groups did not significantly regrow at the primary tumor xenograft site until day 20. Remarkably, tumors of G7* mice (extra $n = 3$; treated same with G7 but cared until day 30) almost disappeared on day 30 without significant regrowth/recurrence since day 20 (Fig. S15). Body weights of mice in the seven treatment groups were maintained without significant change over 20 days, indicating that all mice were well cared for without deleterious effects for the duration of therapy (Fig. 8E). Separately, we demonstrated that the 808 nm laser irradiation alone (1.5 W/cm² for 60 min; no sample injection) seldom elevated the surface tumor temperature and did not suppress the growth of xenograft 4T1 tumors [group H1 ($n = 4$); tumor volume: 1176.0 ± 76.3 mm³] (Fig. S15). Also, the tumor suppression profile of another group H2 ($n = 4$) for Hb₁₀ μ Gel (+UCNPs without Ce6) with 808 nm laser irradiation at mild temperature (41–42 °C) was examined to compare with that of G6 (strong hyperthermia). This new group did not exhibit significant hyperthermal and photodynamic effects due to mild temperature setting and absence of Ce6. The antitumor efficacy of group H2 was much lower than that of G6 but similar with those of G2 or G1 (control PBS) (tumor volume: 962.6 ± 68.0 mm³; Fig. S15).

Tumors obtained from each treatment group were evaluated histologically by hematoxylin and eosin (H&E) staining and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) (Fig. 8F). H&E-stained tumor tissue specimens from G6 and G7 mice exhibited noticeably lower tumor cell density than specimens from the other mouse groups. The strongest TUNEL fluorescence staining was found in 4T1 tumors from groups G6 and G7 treated with strong hyperthermia or continuous ¹O₂ exposure, indicating significant tumor cell apoptosis in these groups. Cytotoxicity was achieved by ROS-mediated apoptosis as well as strong and sudden heat stress. Enhanced tumor oxygenation by Hb₆ μ Gels (+ ascorbic acid & oxygen) and Hb₀ μ Gels (+ PFC + US(+)) was confirmed using the Hydroxyprobe™-1 (pimonidazole HCl) immunofluorescence staining assay for tissue hypoxia. Pimonidazole (2-nitroimidazole), which is specifically reduced and binds to intracellular macromolecules in hypoxic regions of tumors [63,64], was intraperitoneally injected immediately after the sample injections. Tumors were resected at 90 min after the pimonidazole injection. As shown in Fig. 8G, only 4T1 tumors from G4, G5, and G7 mice were not hypoxic, whereas tumors from mice in the PBS group and other groups showed clear green fluorescence, indicating hypoxia. Together, these results indicate that Hb₆ μ Gels can supply oxygen to hypoxic tumor tissues, which can help suppress hypoxic tumor growth. Furthermore, the intratumoral injection of Cy5.5-tagged or naïve Hb₆ μ Gel (+UCNPs/Ce6) resulted in not only negligible accumulation in five major tissue organs (liver, kidney, spleen, lung and heart) but insignificant changes in tissue histology based on H&E staining. This showed that our hemoglobin μ Gels were presumably biocompatible and safe as a promising injectable microgel system because it mainly consisted of generally-regarded biocompatible hemoglobin and albumin proteins (Figs. 8E and S16).

3. Conclusions

In summary, we successfully designed and prepared erythrocyte-like Hb μ Gel systems of 5–6 μ m in size comprising Er@Lu UCNPs and Ce6 photosensitizer and capable of (i) emitting heat, (ii) supplying oxygen, and (iii) generating singlet oxygen in response to 808 nm NIR laser irradiation. Our Hb μ Gels were able to elevate the surrounding temperature by emitting heat in a controlled manner (either strong or mild) and also to generate singlet oxygen under sufficient self-oxygenation due to the activity of UCNPs and the affinity of heme for oxygen. By

varying synthesis conditions, Hb μ Gels can be designed to have either photothermal or photodynamic activity or both to effectively suppress hypoxic tumor spheroids and mice tumors. Mild hyperthermia induced by Hb μ Gels plays a supporting role in killing hypoxic tumor cells because it facilitates the local transport of O₂ and ¹O₂. Importantly, all these abilities can be achieved using a single Hb μ Gel system in combination with NIR laser irradiation. Taken together, our results validate Hb μ Gels as prototype locally injectable microgel platforms for the treatment of hypoxic tumors.

4. Materials and methods

4.1. Materials

Erbium acetate hydrate (III), lutetium acetate hydrate (III), ammonium fluoride (NH₄F), oleic acid, 1-octadecene, ammonium hydroxide solution, polyacrylic acid (Mw 1,800), hemoglobin (Hb; bovine), bovine serum albumin (BSA), and kerosene were purchased from Sigma-Aldrich (St. Louis, MO, USA). Chlorin e6 (Ce6) was purchased from Frontier Scientific (Salt Lake City, UT, USA). Icosafuoro-15-crown-5-ether (PFC) was purchased from Tokyo Chemical Industry Co., LTD. (Tokyo, Japan). SY-Glyster CR-310 was kindly provided by Sakamoto Yakuin Kogyo Co. (Osaka, Japan). 4T1 breast cancer cells were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). LIVE/DEAD™ viability/cytotoxicity assay kits, singlet oxygen sensor green reagent (SOSG), and CellROX™ Green reagent were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Anti-HIF-1 α primary and Alexa Fluor®-488-conjugated goat anti-rabbit secondary antibodies were purchased from Abcam (Cambridge, MA, USA). *In situ* cell death detection (terminal deoxynucleotidyl transferase dUTP nick end labeling: TUNEL) assay kits were purchased from Roche Diagnostics GmbH (Mannheim, Germany). Hypoxyprobe™-1 Plus kits were obtained from Hypoxyprobe Inc. (Burlington, MA, USA). All other reagents were obtained from Sigma-Aldrich unless otherwise indicated.

4.2. Animals

Animals were cared for in accordance with the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. Protocols were also approved by the Institutional Animal Care and Use Committee (IACUC) of Sungkyunkwan University (IACUC number: 202106301, approval date 22 July 2021). BALB/c *nu/nu* mice (male, 6-weeks-old) were purchased from ORIENT BIO (Seongnam, R. O. Korea). Mice were kept in microisolator cages on individually ventilated cage racks, with unrestricted access to an autoclaved standard rodent diet (LabDiet 5008, Purina, St. Louis, MO, USA) and a 12 h light/dark cycle.

4.3. Synthesis of core UCNPs for red emission

Core UCNPs (~30 nm) were fabricated by slight modification of a previously described procedure [27]. Briefly, Er(CH₃CO₂)₃ (6 mmol) in 12 mL methanol was added to a round bottom flask containing 24 mL oleic acid (OA) and 90 mL octadecene (ODE). Methanol was evaporated at 110 °C under vacuum for 25 min, and the reaction temperature was maintained at 150 °C for 1 h under argon flow to obtain a clear solution. After cooling, a methanol solution containing NH₄F (24 mmol) and NaOH (15 mmol) was added slowly to the reaction mixture vessel and kept at 48 °C for 30 min. After removing methanol, the vessel was heated to 308 °C at a rate of 10 °C/min and maintained at this temperature for 90 min under an argon atmosphere. The mixture was cooled to 50 °C, and then 20 mL aliquots of the mixture were mixed with an equal volume of acetone to precipitate the UCNPs. The resulting suspensions were centrifuged at 6554 g for 10 min. Pellets were redispersed in a mixture of OA (6 mL) and ODE (15 mL) to remove impurities as a washing step, and the suspension was further precipitated by the addition of 21 mL acetone. After centrifugation (6554 g for 10 min), pellets were finally collected

and redispersed in 5 mL cyclohexane. Dispersed UCNP were centrifuged at 1000 g for 5 min to remove large particles. Finally, supernatants containing fine UCNP (~25 nm) were harvested and stored at 4 °C for further experiments.

4.4. Synthesis and characterization of core@shell UCNP for red emission

Core@shell (NaErF₄@NaLuF₄) UCNP were prepared by slight modification of a procedure described previously. Briefly, Lu(CH₃CO₂)₃ (3 mmol) in 7.5 mL methanol was added to a round bottom flask containing 24 mL OA and 90 mL ODE. Methanol was evaporated at 110 °C under vacuum for 30 min, and the temperature was kept at 150 °C for 1 h under argon flow to obtain a clear solution. After cooling, as-synthesized core UCNP (300 mg) in cyclohexane were added to the solution, and the solution was heated to 110 °C for 30 min under vacuum to remove cyclohexane. The temperature was decreased to 44 °C prior to slowly adding NH₄F (12 mmol) and NaOH (7.5 mmol) in methanol. After a 30 min incubation period at 48 °C, methanol was evaporated using the process described above. The reaction vessel was heated to 308 °C at a rate of 10 °C/min and maintained at this temperature for 90 min under an argon atmosphere. Pellets were washed and redispersed by the same method described for core UCNP above. Finally, supernatants containing fine Core@shell UCNP (~35 nm) were harvested and stored at 4 °C for further experiments.

4.5. Synthesis and characterization of core@shell UCNP for green/red emission

The conventional core@shell (NaYF₄: Yb, Nd, Er@NaLuF₄) UCNP were synthesized to compare with NaErF₄@NaLuF₄ in terms of emission spectrophotometric pattern at the 808 nm excitation wavelength. For the core structure, 6 mmol each of Y(CH₃CO₂)₃, Yb(CH₃CO₂)₃, Er(CH₃CO₂)₃, and Nd(CH₃CO₂)₃ [by molar ratio, 68.5% Y, 30% Yb, 0.5% Er, 1% Nd] was dissolved in 10 mL methanol. For the shell structure, 2 mmol of each Y(CH₃CO₂)₃ and Nd(CH₃CO₂)₃ [by molar ratio, 80% Y, 20% Nd] was dissolved in 4 mL methanol. All relevant synthesis steps are the same as used for synthesis of the NaErF₄@NaLuF₄ structure described above.

4.6. Preparation of polyacrylic acid-coated core@shell (NaErF₄@NaLuF₄) UCNP

Five milliliters of polyacrylic acid (PAA) in ethanol (40 mg/mL) was added to 5 mL of core@shell UCNP in chloroform (20 mg/mL) and stirred overnight at room temperature. This solution was then centrifuged for 30 min at 14,500 rpm, and PAA-coated-pellets were washed three times with ethanol. Resulting samples were redispersed in PBS (10 mM) and kept at 4 °C.

4.7. Characterization of core@shell UCNP

Particle sizes of a series of UCNP were determined by dynamic light scattering (DLS) (Zetasizer Nano-S90, Malvern Instruments Ltd., Worcestershire, UK) at a 90° scattering angle, and particle sizes (mean ± sd) of representative UCNP from TEM images were also calculated using OriginPro® software (OriginLab®). Irradiation by an 808 nm laser (Laserlab CO, Gyeonggi-do, R. O. Korea) was used to identify the fluorescence emission of UCNP. Morphology of Core@shell UCNP was examined by ultrahigh-resolution analytical electron microscopy (HR-TEM) (JEM-3010, JEOL Ltd., Tokyo, Japan). Element composition of materials was captured by TEM and energy dispersive X-ray spectroscopy (EDS; JEM-ARM200F, JEOL Ltd., Tokyo, Japan). Crystal structures of core and core@shell nanoparticles were confirmed by X-ray powder diffraction (XRD) using a D8 ADVANCE system with Davinci (Bruker AXS GmbH, Karlsruhe, Germany) equipped with Cu Kα radiation and a high speed LynxEye detector. Samples were analyzed over the 2θ range

of 5–65° with 0.02° increments at a rate of 6°/min. Upconversion emission spectra were collected over the range of 380–780 nm using a photoluminescence spectrophotometer (FLS100, Edinburgh Instruments, UK) at the 808 nm excitation wavelength.

4.8. Preparation of hemoglobin microgels

Hemoglobin microgels (μGels) were fabricated by slight modification of Shirasu porous glass (SPG) membrane emulsification [53–55]. Briefly, w/o emulsions containing different concentrations of Hb/BSA (10/6%, 6/10%, and 0/16% (w/v) in distilled water (DW) were prepared using SPG membranes with a pore size of 3 μm. Dispersed and continuous phases were 3 mL mixture solutions of Hb/BSA (300/180, 180/300, and 0/480 mg, respectively) and 150 mL kerosene with 2%. An internal pressure type micro kit (MCTech, Shihung, R. O. Korea) was used for membrane emulsification. The dispersed phase containing hemoglobin or albumin was passed through the pores of a long tube-shaped SPG membrane by nitrogen gas-driven pressure, and the extruded micro-sized droplets were emulsified in oil phase solution by stirring at 220 rpm to induce the formation of hemoglobin microgels. To synthesize UCNP-loaded Hb microgels, Hb, BSA, and PAA-coated core@shell UCNP (180, 300 and 120 mg, respectively) were included in the dispersed phase and emulsified by the same procedure described above.

The resulting w/o emulsion containing Hb/BSA/UCNP liquid microdroplets was mixed with 3 mL 50% glutaraldehyde solution (final concentration of 1.0 v/v%) and stirred at 600 rpm for 3 h for cross-linking. The reaction was quenched by adding milled glycine (final concentration; 0.05 M) and allowed to continue for 30 min. The resulting mixture containing Hb microgels was centrifuged at 6108 g and washed 3 times with 10 mM PBS containing 0.02% Tween 80 and 50% ethanol. Pellets were finally washed with DW, and the resulting Hb μGel solution was briefly filtered through a 10–15 μm mesh strainer to remove aggregated particles and further lyophilized with 3% d-(+)-trehalose dihydrate to prevent aggregation during the lyophilization step. To incorporate Ce6, a portion (20 mg) of the freeze-dried Hb μGel with dissolved UCNP was mixed with 4 mL of Ce6 (100 μg/mL) dissolved in a 1:9 mixed solution of DMSO and DW. The resulting Ce6/Er@Lu UCNP-loaded Hb μGels were briefly centrifuged at 4000 rpm for 3 min. Supernatant was removed, and the μGels were washed three times with PBS and stored at 4 °C for further experiments.

4.9. Characterization of hemoglobin microgels

UCNP-loaded Hb μGels were carefully characterized using various analytical instruments. Two main components of UCNP-loaded Hb μGels, namely Hb and BSA (fluorescein isothiocyanate (FITC) modified), were visualized by confocal laser scanning microscopy (CLSM; LSM510, Carl Zeiss, Jena, Germany) using excitation/emission wavelengths of 549/628 and 495/519 nm, respectively. Surface morphology and red fluorescence of Hb μGels were examined by optical/fluorescence microscopy (ECLIPSE Ts2-FL, Nikon corp., Tokyo, Japan) and field emission scanning electron microscopy (FE-SEM) (JSM7500F, JEOL Ltd, Tokyo, Japan). Cross-sectional UCNP-loaded Hb μGel samples were prepared by focused ion beam (FIB) (JIB-4601 F, JEOL Ltd, Tokyo, Japan) and analyzed by FE-SEM and high-resolution transmission electron microscopy (HR-TEM) (JEM-3010, JEOL Ltd, Tokyo, Japan), respectively. μGel samples were lyophilized for 2 days before analysis. Additionally, UCNP-loaded Hb μGels containing chlorin e6 were visualized by CLSM.

4.10. In vitro and in vivo evaluation of the photothermal effect of hemoglobin microgels

A thermal imaging camera was used to examine the photothermal effect of Hb μGels *in vitro* and *in vivo*. Hb μGel samples (Hb/BSA feed weight ratios: 10:6, 6:10, and 0:16) were placed in 0.5 mL tubes (Costar,

0.5 mL individual PCR tubes). Each microtube was irradiated with 808 nm laser (1.5 W/cm^2) for 20 min. Surface temperature was monitored every minute. Mild hyperthermia ($41\text{--}42 \text{ }^\circ\text{C}$) was induced by 3 min alternation of on/off 808 nm light irradiation. To obtain photothermal images *in vivo*, PBS or Hb μGel samples were injected intratumorally into 4T1-tumor bearing mice and tumor regions were irradiated with 808-nm laser (1.5 W/cm^2) for 15 min. The diameter of the laser spot was adjusted to 1 cm. The following equation was used to calculate the laser output power: laser output power (W) = laser fluence (W/cm^2) \times spot area (cm^2). Temperature increases and thermal images were monitored every minute using a thermographic camera (FLIR E85). Additionally, fluorescence and thermal images of Hb μGel samples mounted on a plate (1 cm diameter) were obtained by thermographic camera and FOBI *in vivo* imaging equipment (NeoScience, Suwon, Korea), respectively.

4.11. Spectrophotometric analysis of hemoglobin microgels

Circular dichroism (CD) spectra from DW, Hb, BSA, and various Hb μGels containing UCNPs were recorded at a concentration of 1 mg/mL in DW using a dichroism spectropolarimeter (J-1500, Jasco International Co., Ltd., USA). The far UV region was scanned between 190 nm and 260 nm. UV-VIS absorption patterns of Hb μGels were monitored in the wavelength range of 350–550 nm using UV-VIS spectrophotometry according to the presence of ascorbic acid and/or oxygen.

4.12. Preparation of perfluorocarbon (PFC)-based albumin nano-emulsion (PFC/BSA-NE) and PFC/UCNP-loaded Hb₀ μGels

A portion (250 μL) of icosafuoro-15-crown-5-ether (PFC) was added to 2.5 mL PBS solution containing 40 mg BSA. The mixture was then placed in an ice bath and ultrasonicated for 200 s at 20% amplitude (operation 8 s, interval 2 s). The obtained emulsion was centrifuged (8000 rpm, 3 min) and redispersed in 0.5 mL PBS. Separately, 0.5 mL of PFC/BSA-NE (40 mg and 250 μL BSA and PFC, respectively) was mixed with 2.5 mL dispersed phase containing 440 mg BSA and 120 mg UCNPs. Hb₀ μGels were fabricated using the same procedure described above for SPG membrane emulsification and microgel hardening.

4.13. Singlet oxygen ($^1\text{O}_2$) generation by UCNP-loaded Hb μGel

Singlet oxygen generation from UCNP-loaded Hb μGels was detected using singlet oxygen sensor green (SOSG) reagent. Samples were divided into six groups (I) PBS; (II) Hb₆ μGel (Hb:BSA = 6:10) + N₂ for hypoxia; (III) Hb₆ μGel + O₂ for oxygenation; (IV) Hb₆ μGel + ascorbic acid + O₂; (V) PFC/BSA-NE-loaded Hb₀ μGel + O₂ + US(+); (VI) PFC/BSA-NE-loaded Hb₀ μGel + O₂ + US(−). Hypoxic samples were placed in a 48-well plate pre-filled with a hypoxic solution (DW:DMSO = 9:1, hypoxic chamber overnight). Hypoxia was achieved by incubating 48-well plates in a hypoxic gas stream (5% CO₂:95% N₂ on a volume basis). Oxygenated samples were prepared under oxygen gas flow for 20 min. All samples were mixed with SOSG reagent (final concentration 5 μM) and quickly added to hypoxic solution in the wells of a 48-well plate using a needle syringe through an adhesive plate cover. Each well was irradiated by 808-nm laser (1.5 W/cm^2) for 60 min. While irradiating the sample wells with the laser for 60 min, a 100 μL aliquot of each sample was collected every 10 min. A multi-mode microplate reader was used to measure the intensity of the green fluorescence (excitation and emission wavelengths of 485 and 538 nm, respectively) emitted from SOSG induced by $^1\text{O}_2$ production. Mild ultrasound (1 MHz, 3 W/cm^2) was applied to sample group V. All samples were transferred to a black 96-well plate for fluorescence detection. The SOSG fluorescence signal was visualized using an FOBI *in vivo* imaging system (NeoScience, Suwon, Korea).

4.14. Measurement of O₂ release

Oxygen concentration (ppm; mg/L) in aqueous solutions purged with N₂ gas was determined by oxygen meter (PreSens, Regensburg, Germany) before and after adding the following samples: (I) Hb₆ μGel (Hb:BSA = 6:10) + N₂ (nitrogen gas) for hypoxia; (II) Hb₆ μGel + O₂ for oxygenation; (III) Hb₆ μGel + ascorbic acid + O₂; (IV) PFC/BSA-NE-loaded Hb₀ μGel + O₂ + US(+); (V) PFC/BSA-NE-loaded Hb₀ μGel + O₂ + US(−). The oxygen concentration of PFC/BSA-NE-loaded Hb₀ μGel was measured with and without ultrasound treatment (1 MHz, 3 W/cm^2). Oxygen content of hypoxic medium in a 200 μL vial was measured for the first 300 s to record hypoxic conditions, samples were added into the vial, and measurements were performed for an additional 300 s. External US treatment was applied to one tube for another 300 s. Oxygen concentrations of all samples were measured for a total of 1500 s. Hypoxic conditions were maintained by N₂ gas purging for 10 min (N₂ flow rate = 0.1 MPa).

4.15. Fluorescence visualization by CLSM of Hb μGel & 4T1 cell spheroids

4T1 cell spheroids were prepared in a V-bottom 96-well plate (Shimadzu, Tokyo, Japan). 4T1 cells (100 μL , 4×10^4 cells/mL) were seeded into each well and cultured for 72 h. Spheroids were transferred to 96-well plates with a U-shaped bottom, and the media was replenished with 100 μL DMEM medium containing 1% FBS and 1% penicillin/streptomycin (P/S; Corning, NY, USA). 4T1 cell spheroids were plated in each well of an 8-well chamber (Ibidi, Martinsried, Germany) and stained with Hoechst. Spheroids were mixed with Hb₆ μGels and visualized by CLSM (Carl Zeiss, Jena, Germany) to observe the effects of the microgels on the spheroids.

4.16. HIF-1 α visualization of 3D 4T1 cell spheroids

Prepared 4T1 cell spheroids were treated with (I) PBS under normoxic or hypoxic conditions, (II) Hb₆ μGel under normoxic or hypoxic conditions, (III) Hb₆ μGel + ascorbic acid + O₂ in sealed hypoxic media plate wells; and (IV) PFC/BSA-NE-loaded Hb₀ μGel + O₂ + US(+) in sealed hypoxic media plate wells. Spheroids were fixed in 4% formaldehyde for 10 min before incubation in 0.1% Triton X-100 for 5 min. Spheroids were then incubated with 1% BSA and PBS with 0.2% Tween 80 containing glycine (22.5 mg/mL) for 1 h to block nonspecific binding of antibodies. Spheroids were treated with a 1/50 dilution of anti-HIF-1 α antibody-Alexa Fluor 488 and incubated overnight at 4 $^\circ\text{C}$ (Abcam, Cambridge, USA), and nuclei were stained with Hoechst. Samples were observed using CLSM.

4.17. ROS deep assay

Prepared 4T1 cell spheroids were treated with (I) UCNP-loaded Hb₆ μGel + Ce6 under normoxic conditions with or without 808 nm laser irradiation, (II) UCNP-loaded Hb₆ μGel + ascorbic acid/Ce6 + O₂ in sealed hypoxic media plate wells with or without 808 nm laser irradiation, and (III) UCNPs and PFC/BSA-NE-loaded Hb₀ μGel + Ce6 + O₂ + US(+) in sealed hypoxic media plate wells. Under normoxic and hypoxic conditions, ROS detection was carried out during laser irradiation (wavelength of 808 nm) for 30 min. CellROX[®] reagent was applied to spheroids at a final concentration of 20 μM , followed by a 30 min incubation at 37 $^\circ\text{C}$. 4T1 cell spheroids were washed three times with PBS and stained with DAPI. CLSM (Carl Zeiss, Jena, Germany) was used to observe the production and distribution of reactive oxygen species (ROS) inside cells.

4.18. *In vitro* cytotoxicity of 4T1 cell spheroids using the LIVE/DEAD™ assay

First, the photodynamic effect of UCNP-loaded Hb₆ μGels on the viability of cell spheroids was assessed under the following hypoxic conditions: (I) UCNP-loaded Hb₆ μGel + Ce6 with or without 808 nm laser irradiation, (II) UCNP-loaded Hb₆ μGel + ascorbic acid/Ce6 + O₂ in sealed hypoxic media plate wells with or without 808 nm laser irradiation, and (III) UCNP and PFC/BSA-NE loaded Hb₀ μGel + Ce6 + O₂ + US(+) in sealed hypoxic media plate wells with or without 808 nm laser irradiation. Samples were irradiated at 808 nm for 30 min in the dark. Ascorbic acid was added into the Hb₆ μGel, and oxygenation by O₂ purging was conducted for 10 min. For group III, ultrasound (1 MHz, 3 W/cm²) was applied to wells containing spheroids and microgels before laser irradiation. Additionally, spheroids were treated with (I) PBS and 808 nm laser, (II) UCNP-loaded Hb₀ μGel (20 mg/mL) + Ce6 with or without 808 nm laser irradiation, and (III) Hb₆ μGel (30 mg/mL) with or without 808 nm laser irradiation. These were considered the respective negative control, PDT only, and PTT only groups. Additionally, the following spheroid groups were designated: (I) mild PTT + PDT, (II) mild PTT for target temperature of 41–42 °C, and (iii) strong PTT for a target temperature >48 °C under normoxic conditions. To create these groups, spheroids were treated with (I) UCNP-loaded Hb₆ μGel (20 mg/mL) + ascorbic acid/Ce6 with or without 808 nm laser irradiation (1.5 W/cm²), (II) Hb₆ μGel (20 mg/mL) with or without 808 nm laser irradiation (1.5 W/cm²), and (III) Hb₆ μGel (40 mg/mL) with or without 808 nm laser irradiation (1.5 W/cm²). After laser treatment, spheroids were washed three times with DPBS, and the medium was replenished with fresh 1% FBS and 1% P/S DMEM and placed in a CO₂ chamber overnight. Spheroids were then stained with Calcein-AM (for live cells) and ethidium homodimer-1 (for dead cells). Subsequently, stained cells were observed by CLSM using excitation/emission wavelengths of 494/517 nm for Calcein-AM and 528/617 nm for ethidium homodimer-1, respectively. Hypoxia was achieved by incubation in a hypoxic chamber under a hypoxic gas stream (5% CO₂:95% N₂ on a volume basis). In addition, relevant samples were placed in hypoxic media prior to oxygen generation.

4.19. Evaluation of the *in vitro* cytotoxicity of Hb μGels

Cytotoxic effects of gels against 4T1 cells (breast cancer cell line) were assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based assay. 4T1 cells were seeded at 1×10^4 cells/well in 96-well plates and pre-incubated for 24 h in DMEM media containing 10% FBS and 1% P/S. After replacing the cell culture medium with DMEM media, cells were washed twice with DPBS. Cells were treated with the various Hb μGel samples (Hb₀ μGel, Hb₆ μGel, and Hb₁₀ μGel: 100 μL) at different concentrations for 4 h μGels were removed from the plates by washing with DPBS. Cell viability **cell viability** was analyzed using the MTT assay.

4.20. Visualization of 4T1 cell-xenografted mice injected with UCNP-loaded Hb microgels

The injection site of UCNP-loaded Hb μGels was monitored by computerized tomography (CT; SKY-scan 1076, Broker, USA) at 0, 1, and 7 days. Cy5.5-Hb μGel, which was modified with Cy5.5-NHS (GE Healthcare, Chicago, USA), was injected directly into the tumors of 4T1 cell-xenografted mice, and fluorescence signals were visualized at pre-determined times and at wavelengths corresponding to Cy5.5 and hemoglobin using FOBI *in vivo* imaging equipment (NeoScience, Suwon, R. O. Korea). Separately, the major organs (liver, kidney, spleen, lung and heart) of the mouse were excised and visualized at 24 h after sacrifice of mice.

4.21. Photoacoustic (PA) imaging to detect oxygen generation

Oxygen levels inside xenografted 4T1 tumors were monitored after injecting various samples using photoacoustic (PA) imaging. When tumors reached ~150 mm³ in volume, mice were treated with (I) PBS, (II) hypoxic Hb₆ μGel, (III) Hb₀ μGel + PFC + US(-), (IV) Hb₀ μGel + PFC + US(+), and (V) Hb₆ μGel + ascorbic acid + O₂. Tumor oxygenation (as oxyhemoglobin: HbO₂ ratio) was visualized and recorded using a Vevo® LAZR-X Multimodal Imaging System (FujiFilm, VisualSonics Inc., Minato, Tokyo, Japan) set to oxy-hem mode (750 and 850 nm) before injection (-5 min) and at 0, 5, 15, 30, and 60 min after injection. Average oxygen level histograms showed pixel-based oxygen saturation percentages.

4.22. *In vivo* antitumor efficacy

4T1 cells (100 μL, 2×10^6 cells) were subcutaneously injected into the dorsal flanks of mice. When the volume of the tumors reached 120–150 mm³, mice were randomly divided into seven groups as follows: G1 - PBS (non-treated); G2 - Hb₆ μGel + 808 nm (+) under a mild temperature (41–42 °C) setting; G3 - Hb₀ μGel (+UCNPs/Ce6) previously treated with nitrogen to maintain a hypoxic state + 808 nm (+) (1.5 W/cm² for 20 min); G4 - Hb₆ μGel (+UCNPs/Ce6) + ascorbic acid + O₂ + 808 nm (-); G5 - Hb₀ microgel (+UCNPs/Ce6) + PFC + O₂ + 808 nm (+) + US(+) (60 min); G6 - Hb₁₀ μGel (+UCNPs) + 808 nm (+) (1.5 W/cm² for 30 min) under strong hyperthermia (>48 °C) and G7 - Hb₆ μGel (+UCNPs/Ce6) + ascorbic acid + O₂ + 808 nm (+) under a mild temperature (41–42 °C) setting. Tumor size was measured every day, and volume (V) was calculated using equation $V = 0.5 \times A \times B^2$, where A is the longest diameter (mm), and B is the shortest diameter (mm). Each sample (50 μL; 20 mg/mL of μGel) was intratumorally injected into a mouse. Body weights of mice in all groups were measured every day. On day 20, mice were sacrificed, and their tumors were excised and photographed (n = 4). For H&E and TUNEL staining, tumors and major organs (liver, kidney, spleen, lung and heart) of all mice were dissected and paraffin sections were prepared. H&E and TUNEL staining were performed according to the manufacturers' protocols, and cells were examined by digital CLSM.

Separately, the G7* mice (n = 3), which were treated same with G7 but cared until day 30, were carefully monitored in terms of tumor volume and body weight. Additional two groups of mice (each n = 4), H1 and H2, were treated with (i) only 808 nm laser irradiation alone (1.5 W/cm² for 60 min) and (ii) Hb₁₀ μGel (+UCNPs without Ce6) with 808 nm laser irradiation at a mild temperature setting (41–42 °C). Their tumor volumes and body weights were measured.

4.23. *In vivo* hypoxia assay

The *in vivo* hypoxia assay was performed by slight modification of a protocol described previously. Mice with ~300 mm³ tumors were treated with a fixed concentration of one of the μGels and then intraperitoneally injected with pimonidazole hydrochloride (200 mg/kg) (Hypoxyprobe™-1 Plus Kit; Hypoxyprobe Inc. Burlington, MA, USA). After 90 min, tumors were surgically resected for frozen sectioning. For immunofluorescence staining, paraffin sections of tumors were prepared and treated with mouse anti-pimonidazole primary antibody (dilution 1:200, Hypoxyprobe Inc.) and Alexa 488-conjugated goat anti-mouse secondary antibody (dilution 1:200, Jackson Inc.) according to the kit instructions. Nuclei were stained with DAPI (dilution 1:5000, Invitrogen, Waltham, MA, USA). Slices were observed by CLSM.

CRediT authorship contribution statement

Hanju Kim: Data curation, Methodology, Investigation, Writing – original draft. **Johyun Yoon:** Data curation, Methodology. **Hwang Kyung Kim:** Data curation, Methodology. **Woo Tak Lee:** Data curation,

Investigation. **Nguyen Thi Nguyen**: Data curation. **Xuan Thien Le**: Data curation, Investigation. **Eun-Hee Lee**: Data curation, Methodology. **Eun Seong Lee**: Supervision. **Kyung Taek Oh**: Supervision. **Han-Gon Choi**: Supervision. **Yu Seok Youn**: Conceptualization, Writing – original draft, Writing – review & editing, Supervision, Project administration, Funding acquisition.

Declaration of competing interest

The authors have no conflicts of interest to declare.

Acknowledgments

This work was supported by a National Research Foundation of Korea (NRF) grants funded by the Korean government (No. NRF-2019R1A5A2027340) and the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. NRF-2022M3A9G8017220).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bioactmat.2022.09.020>.

References

- [1] A.I. Alayash, Oxygen therapeutics: can we tame haemoglobin? *Nat. Rev. Drug Discov.* 3 (2) (2004) 152–159, <https://doi.org/10.1038/nrd1307>.
- [2] M.M. Jansman, L. Hosta-Rigau, Recent and prominent examples of nano- and microarchitectures as hemoglobin-based oxygen carriers. *Adv. Colloid Interface Sci.* 260 (2018) 65–84, <https://doi.org/10.1016/j.cis.2018.08.006>.
- [3] Z. Tao, P.P. Ghoroghchian, Microparticle, nanoparticle, and stem cell-based oxygen carriers as advanced blood substitutes. *Trends Biotechnol.* 32 (9) (2014) 466–473, <https://doi.org/10.1016/j.tibtech.2014.05.001>.
- [4] R.M. Winslow, MP4, a new nonvasoactive polyethylene glycol–hemoglobin conjugate. *Artif. Organs* 28 (9) (2004) 800–806, <https://doi.org/10.1111/j.1525-1594.2004.07392.x>.
- [5] P. Cabrales, Examining and mitigating acellular hemoglobin vasoactivity. *Antioxid. redox signal.* 18 (17) (2013) 2329–2341, <https://doi.org/10.1089/ars.2012.4922>.
- [6] K.D. Vandegriff, R.M. Winslow, Hemospan: design principles for a new class of oxygen therapeutic. *Artif. Organs* 33 (2) (2009) 133–138, <https://doi.org/10.1111/j.1525-1594.2008.00697.x>.
- [7] M. Pilarek, Liquid perfluorochemicals as flexible and efficient gas carriers applied in bioprocess engineering: an updated overview and future prospects. *Chem. Process Eng.* 35 (4) (2014) 463–487, <https://doi.org/10.2478/cpe-2014-0035>.
- [8] S. Sadrzadeh, E. Graf, S.S. Panter, P. Hallaway, J. Eaton, Hemoglobin. A biologic fenton reagent. *J. Biol. Chem.* 259 (23) (1984) 14354–14356, [https://doi.org/10.1016/S0021-9258\(17\)42604-4](https://doi.org/10.1016/S0021-9258(17)42604-4).
- [9] B.R. Van Dyke, P. Saltman, Hemoglobin: a mechanism for the generation of hydroxyl radicals. *Free Radic. Biol. Med.* 20 (7) (1996) 985–989, [https://doi.org/10.1016/0891-5849\(95\)02186-8](https://doi.org/10.1016/0891-5849(95)02186-8).
- [10] L. Duan, X. Yan, A. Wang, Y. Jia, J. Li, Highly loaded hemoglobin spheres as promising artificial oxygen carriers. *ACS Nano* 6 (8) (2012) 6897–6904, <https://doi.org/10.1021/nn301735u>.
- [11] W. Tang, Z. Zhen, M. Wang, H. Wang, Y.J. Chuang, W. Zhang, G.D. Wang, T. Todd, T. Cowger, H. Chen, Red blood cell-facilitated photodynamic therapy for cancer treatment. *Adv. Funct. Mater.* 26 (11) (2016) 1757–1768, <https://doi.org/10.1002/adfm.201504803>.
- [12] N. Doshi, A.S. Zahr, S. Bhaskar, J. Lahann, S. Mitragotri, Red blood cell-mimicking synthetic biomaterial particles. *Proc. Natl. Acad. Sci. USA* 106 (51) (2009) 21495–21499, <https://doi.org/10.1073/pnas.0907127106>.
- [13] S. Kizaka-Kondoh, M. Inoue, H. Harada, M. Hiraoka, Tumor hypoxia: a target for selective cancer therapy. *Cancer Sci.* 94 (12) (2003) 1021–1028, <https://doi.org/10.1111/j.1349-7006.2003.tb01395.x>.
- [14] J.M. Brown, W.R. Wilson, Exploiting tumour hypoxia in cancer treatment. *Nat. Rev. Cancer* 4 (6) (2004) 437–447, <https://doi.org/10.1038/nrc1367>.
- [15] S. Rey, L. Schito, M. Koritzinsky, B.G. Wouters, Molecular targeting of hypoxia in radiotherapy. *Adv. Drug Deliv. Rev.* 109 (15) (2017) 45–62, <https://doi.org/10.1016/j.addr.2016.10.002>.
- [16] C.-C. Huang, W.-T. Chia, M.-F. Chung, K.-J. Lin, C.-W. Hsiao, C. Jin, W.-H. Lim, C.-C. Chen, H.-W. Sung, An implantable depot that can generate oxygen in situ for overcoming hypoxia-induced resistance to anticancer drugs in chemotherapy. *J. Am. Chem. Soc.* 138 (16) (2016) 5222–5225, <https://doi.org/10.1021/jacs.6b01784>.
- [17] G. Yang, L. Xu, Y. Chao, J. Xu, X. Sun, Y. Wu, R. Peng, Z. Liu, Hollow MnO₂ as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. *Nat. Commun.* 8 (1) (2017) 1–13, <https://doi.org/10.1038/s41467-017-01050-0>.
- [18] H. Chen, J. Tian, W. He, Z. Guo, H₂O₂-activatable and O₂-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. *J. Am. Chem. Soc.* 137 (4) (2015) 1539–1547, <https://doi.org/10.1021/ja511420n>.
- [19] Y. Cheng, H. Cheng, C. Jiang, X. Qiu, K. Wang, W. Huan, A. Yuan, J. Wu, Y. Hu, Perfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapy. *Nat. Commun.* 6 (1) (2015) 1–8, <https://doi.org/10.1038/ncomms9785>.
- [20] X. Song, L. Feng, C. Liang, K. Yang, Z. Liu, Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperofluorocarbon to overcome hypoxia-associated resistance in cancer therapies. *Nano Lett.* 16 (10) (2016) 6145–6153, <https://doi.org/10.1021/acs.nanolett.6b02365>.
- [21] P. Prasad, C.R. Gordijo, A.Z. Abbasi, A. Maeda, A. Ip, A.M. Rauth, R.S. DaCosta, X. Y. Wu, Multifunctional albumin–MnO₂ nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response. *ACS Nano* 8 (4) (2014) 3202–3212, <https://doi.org/10.1021/nn405773r>.
- [22] S. Gao, G. Wang, Z. Qin, X. Wang, G. Zhao, Q. Ma, L. Zhu, Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound-imaging guided tumor photodynamic therapy. *Biomaterials* 112 (2017) 324–335, <https://doi.org/10.1016/j.biomaterials.2016.10.030>.
- [23] C. Lee, K. Lim, S.S. Kim, E.S. Lee, K.T. Oh, H.-G. Choi, Y.S. Youn, Chlorolla-gold nanorods hydrogels generating photosynthesis-derived oxygen and mild heat for the treatment of hypoxic breast cancer. *J. Contr. Release* 294 (28) (2019) 77–90, <https://doi.org/10.1016/j.jconrel.2018.12.011>.
- [24] L. Chen, W. Wang, J. Tian, F. Bu, T. Zhao, M. Liu, R. Lin, F. Zhang, M. Lee, D. Zhao, Imparting multi-functionality to covalent organic framework nanoparticles by the dual-ligand assistant encapsulation strategy. *Nat. Commun.* 12 (1) (2021) 1–10, <https://doi.org/10.1038/s41467-021-24838-7>.
- [25] L. Chen, T. Zhao, M. Zhao, W. Wang, C. Sun, L. Liu, Q. Li, F. Zhang, D. Zhao, X. Li, Size and charge dual-transformable mesoporous nanoassemblies for enhanced drug delivery and tumor penetration. *Chem. Sci.* 11 (10) (2020) 2819–2827, <https://doi.org/10.1039/C9SC06260B>.
- [26] P. Avci, A. Gupta, M. Sadasivam, D. Vecchio, Z. Pam, N. Pam, M.R. Hamblin, Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. *Semin. Cutan. Med. Surg.* 32 (1) (2013) 41–52.
- [27] S.S. Lucky, K.C. Soo, Y. Zhang, Nanoparticles in photodynamic therapy. *Chem. Rev.* 115 (4) (2015) 1990–2042, <https://doi.org/10.1021/cr5004198>.
- [28] W.T. Lee, J. Yoon, S.S. Kim, H. Kim, N.T. Nguyen, X.T. Le, E.S. Lee, K.T. Oh, H.-G. Choi, Y.S. Youn, Combined Antitumor Therapy Using In Situ Injectable Hydrogels Formulated with Albumin Nanoparticles Containing Indocyanine Green, Chlorin e₆, and Perfluorocarbon in Hypoxic Tumors. *Pharmaceutics* 14 (1) (2022) 148, <https://doi.org/10.3390/pharmaceutics14010148>.
- [29] K. Lim, H.K. Kim, X.T. Le, N.T. Nguyen, E.S. Lee, K.T. Oh, H.-G. Choi, Y.S. Youn, Highly red light-emitting erbium-and lutetium-doped core-shell upconverting nanoparticles surface-modified with PEG-folic acid/TCPP for suppressing cervical cancer HeLa cells. *Pharmaceutics* 12 (11) (2020) 1102, <https://doi.org/10.3390/pharmaceutics12111102>.
- [30] S. He, N.J. Johnson, V.A. Nguyen Huu, Y. Huang, A. Almutairi, Leveraging spectral matching between photosensitizers and upconversion nanoparticles for 808 nm-activated photodynamic therapy. *Chem. Mater.* 30 (12) (2018) 3991–4000, <https://doi.org/10.1021/acs.chemmater.7b04700>.
- [31] Z. Gu, L. Yan, G. Tian, S. Li, Z. Chai, Y. Zhao, Recent advances in design and fabrication of upconversion nanoparticles and their safe theranostic applications. *Adv. Mater.* 25 (28) (2013) 3758–3779, <https://doi.org/10.1002/adma.201301197>.
- [32] S. Wilhelm, Perspectives for upconverting nanoparticles. *ACS Nano* 11 (11) (2017) 10644–10653, <https://doi.org/10.1021/acsnano.7b07120>.
- [33] D. Jaque, L.M. Maestro, B. del Rosal, P. Haro-Gonzalez, A. Benayas, J. Plaza, E. M. Rodríguez, J.G. Solé, Nanoparticles for photothermal therapies. *Nanoscale* 6 (16) (2014) 9494–9530, <https://doi.org/10.1039/C4NR00708E>.
- [34] C. Song, A. Shakil, J. Osborn, K. Iwata, Tumour oxygenation is increased by hyperthermia at mild temperatures. *Int. J. Hyperther.* 12 (3) (1996) 367–373, <https://doi.org/10.3109/02656739609022525>.
- [35] K. Okajima, R.J. Griffin, K. Iwata, A. Shakil, C.W. Song, Tumor oxygenation after mild-temperature hyperthermia in combination with carbogen breathing: dependence on heat dose and tumor type. *Radiat. Res.* 149 (3) (1998) 294–299, <https://doi.org/10.2307/3579963>.
- [36] A. Shakil, J.L. Osborn, C.W. Song, Changes in oxygenation status and blood flow in a rat tumor model by mild temperature hyperthermia. *Int. J. Radiat. Oncol. Biol. Phys.* 43 (4) (1999) 859–865, [https://doi.org/10.1016/s0360-3016\(98\)00516-1](https://doi.org/10.1016/s0360-3016(98)00516-1).
- [37] P. Wust, B. Hildebrandt, G. Sreenivasa, B. Rau, J. Gellermann, H. Riess, R. Felix, P. Schlag, Hyperthermia in combined treatment of cancer. *Lancet Oncol.* 3 (8) (2002) 487–497, [https://doi.org/10.1016/s1470-2045\(02\)00818-5](https://doi.org/10.1016/s1470-2045(02)00818-5).
- [38] F.K. Storm, Clinical hyperthermia and chemotherapy. *Radiol. Clin.* 27 (3) (1989) 621–627.
- [39] P.T.T. Pham, X.T. Le, H. Kim, H.K. Kim, E.S. Lee, K.T. Oh, H.-G. Choi, Y.S. Youn, Indocyanine green and curcumin Co-loaded nano-fireball-like albumin nanoparticles based on near-infrared-induced hyperthermia for tumor ablation. *Int. J. Nanomed.* 15 (2020) 6469, <https://doi.org/10.2147/IJN.S262690>.
- [40] C. Lee, H.S. Hwang, S. Lee, B. Kim, J.O. Kim, K.T. Oh, E.S. Lee, H.G. Choi, Y. S. Youn, Rabies virus-inspired silica-coated gold nanorods as a photothermal therapeutic platform for treating brain tumors. *Adv. Mater.* 29 (13) (2017), 1605563, <https://doi.org/10.1002/adma.201605563>.
- [41] L. Zhang, D. Wang, K. Yang, D. Sheng, B. Tan, Z. Wang, H. Ran, H. Yi, Y. Zhong, H. Lin, Mitochondria-targeted artificial “nano-RBCs” for amplified synergistic

- cancer phototherapy by a single NIR irradiation, *Adv. Sci.* 5 (8) (2018), 1800049, <https://doi.org/10.1002/advs.201800049>.
- [42] S. Park, H. Kim, S.C. Lim, K. Lim, E.S. Lee, K.T. Oh, H.-G. Choi, YSJJCR, Youn, Gold nanocluster-loaded hybrid albumin nanoparticles with fluorescence-based optical visualization and photothermal conversion for tumor detection/ablation, *J. Contr. Release* 304 (28) (2019) 7–18, <https://doi.org/10.1016/j.jconrel.2019.04.036>.
- [43] X. Li, R. Wang, F. Zhang, D. Zhao, Engineering homogeneous doping in single nanoparticle to enhance upconversion efficiency, *Nano Lett.* 14 (6) (2014) 3634–3639, <https://doi.org/10.1021/nl501366x>.
- [44] M.D. Wisser, S. Fischer, C. Siefe, A.P. Alivisatos, A. Salleo, J.A. Dionne, Improving quantum yield of upconverting nanoparticles in aqueous media via emission sensitization, *Nano Lett.* 18 (4) (2018) 2689–2695, <https://doi.org/10.1021/acs.nanolett.8b00634>.
- [45] S. Fischer, N.D. Bronstein, J.K. Swabeck, E.M. Chan, A.P. Alivisatos, Precise tuning of surface quenching for luminescence enhancement in core-shell lanthanide-doped nanocrystals, *Nano Lett.* 16 (11) (2016) 7241–7247, <https://doi.org/10.1021/acs.nanolett.6b03683>.
- [46] R. Singh, G. Dumlupinar, S. Andersson-Engels, S. Melgar, Emerging applications of upconverting nanoparticles in intestinal infection and colorectal cancer, *Int. J. Nanomed.* 14 (2019) 1027–1038, <https://doi.org/10.2147/IJN.S188887>.
- [47] B. Chen, F. Wang, Emerging frontiers of upconversion nanoparticles, *Trends Chem* 2 (5) (2020) 427–439, <https://doi.org/10.1016/j.trechm.2020.01.008>.
- [48] G. Chen, H. Qiu, P.N. Prasad, X. Chen, Upconversion nanoparticles: design, nanochemistry, and applications in theranostics, *Chem. Rev.* 114 (10) (2014) 5161–5214, <https://doi.org/10.1021/cr400425h>.
- [49] D. Chen, M. Xu, M. Ma, P. Huang, Effects of Er³⁺ spatial distribution on luminescence properties and temperature sensing of upconverting core-shell nanocrystals with high Er³⁺ content, *Dalton Trans.* 46 (44) (2017) 15373–15385, <https://doi.org/10.1039/C7DT02915B>.
- [50] L. Zhao, J. Peng, Q. Huang, C. Li, M. Chen, Y. Sun, Q. Lin, L. Zhu, F. Li, Near-infrared photoregulated drug release in living tumor tissue via yolk-shell upconversion nanocages, *Adv. Funct. Mater.* 24 (3) (2014) 363–371, <https://doi.org/10.1002/adfm.201302133>.
- [51] P. Ramasamy, J. Kim, Combined plasmonic and upconversion rear reflectors for efficient dye-sensitized solar cells, *Chem. Commun.* 50 (7) (2014) 879–881, <https://doi.org/10.1039/C3CC47290F>.
- [52] S. Wang, K. Han, S. Ma, X. Qi, L. Guo, X. Li, Blood cells as supercarrier systems for advanced drug delivery, *Med. Drug Discov.* 13 (2022), 100119, <https://doi.org/10.1016/j.medidd.2021.100119>.
- [53] Y.T. Lai, M. Sato, S. Ohta, K. Akamatsu, S.-i. Nakao, Y. Sakai, T. Ito, Preparation of uniform-sized hemoglobin–albumin microspheres as oxygen carriers by Shirasu porous glass membrane emulsification technique, *Colloids Surf. B Biointerfaces* 127 (2015) 1–7, <https://doi.org/10.1016/j.colsurfb.2015.01.018>.
- [54] Y.T. Lai, S. Ohta, K. Akamatsu, S.-i. Nakao, Y. Sakai, T. Ito, Size-dependent interaction of cells and hemoglobin–albumin based oxygen carriers prepared using the SPG membrane emulsification technique, *Biotechnol. Prog.* 31 (6) (2015) 1676–1684, <https://doi.org/10.1002/btpr.2170>.
- [55] S. Ohta, K. Hashimoto, X. Fu, M. Kamihira, Y. Sakai, T. Ito, Development of human-derived hemoglobin–albumin microspheres as oxygen carriers using Shirasu porous glass membrane emulsification, *J. Biosci. Bioeng.* 126 (4) (2018) 533–539, <https://doi.org/10.1016/j.jbiosc.2018.04.017>.
- [56] S.F. Himmelstoß, T. Hirsch, Long-term colloidal and chemical stability in aqueous media of NaYF₄-type upconversion nanoparticles modified by ligand-exchange, *Part. Part. Syst. Charact.* 36 (10) (2019), 1900235, <https://doi.org/10.1002/ppsc.201900235>.
- [57] H. Keum, D. Yoo, S. Jon, Photomedicine based on heme-derived compounds, *Adv. Drug Deliv. Rev.* 182 (2022), 114134, <https://doi.org/10.1016/j.addr.2022.114134>.
- [58] J.F. Lovell, C.S. Jin, E. Huynh, H. Jin, C. Kim, J.L. Rubinstein, W.C. Chan, W. Cao, L.V. Wang, G. Zheng, Porphyrin nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents, *Nat. Mater.* 10 (4) (2011) 324–332, <https://doi.org/10.1038/nmat2986>.
- [59] C. Lee, K. Lim, S.S. Kim, E.S. Lee, K.T. Oh, H.-G. Choi, Y.S. Youn, Near infrared light-responsive heat-emitting hemoglobin hydrogels for photothermal cancer therapy, *Colloids Surf. B Biointerfaces* 176 (2019) 156–166, <https://doi.org/10.1016/j.colsurfb.2018.12.070>.
- [60] C. Heckl, A. Lang, A. Rühm, R. Sroka, T. Duffield, M. Vogeser, M. Paal, Spectrophotometric evaluation of hemolysis in plasma by quantification of free oxyhemoglobin, methemoglobin, and methemalbumin in presence of bilirubin, *J. Biophot.* 14 (5) (2021), e202000461, <https://doi.org/10.1002/jbio.202000461>.
- [61] F.D. Martínez-Mancera, J.L. Hernández-López, In vitro observation of direct electron transfer of human haemoglobin molecules on glass/tin-doped indium oxide electrodes, *J. Mex. Chem. Soc.* 59 (4) (2015) 302–307, <https://doi.org/10.5772/67806>.
- [62] Y. Jin, D. Ni, L. Gao, X. Meng, Y. Lv, F. Han, H. Zhang, Y. Liu, Z. Yao, X. Feng, Harness the power of upconversion nanoparticles for spectral computed tomography diagnosis of osteosarcoma, *Adv. Funct. Mater.* 28 (33) (2018), 1802656, <https://doi.org/10.1002/adfm.201802656>.
- [63] J. Raleigh, S. Chou, G. Arteel, M. Horsman, Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors, *Radiat. Res.* 151 (5) (1999) 580–589, <https://doi.org/10.2307/3580034>.
- [64] X.-F. Li, S. Carlin, M. Urano, J. Russell, C.C. Ling, J.A. O'Donoghue, Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy, *Cancer Res.* 67 (16) (2007) 7646–7653, <https://doi.org/10.1158/0008-5472.CAN-06-4353>.